Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292782 | 0.88 | TSHR (0.75) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL7317557 | 0.87 | TSHR (0.62) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL2588477 | 0.86 | TSHR (0.67) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL10609393 | 0.85 | TSHR (0.60) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL18913824 | 0.84 | TSHR (0.69) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL30758863 | 0.84 | TSHR (0.69) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL10607589 | 0.84 | TSHR (0.58) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL10610874 | 0.84 | TSHR (0.58) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL10608769 | 0.84 | TSHR (0.58) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL10607513 | 0.84 | TSHR (0.58) | TSHRLOXL2KCNJ1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102690269-B | Trifluoro methyl substituted quinoline or quinoxaline compound and preparation method thereof, and pharmaceutical composition containing the compound and purpose thereof | SHANGHAI INST MATERIA MEDICA | 2015-01-07 | — | — | CN | claimed |
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | CHATTOPADHYAYA JYOTI (SE) | 2004-07-22 | — | — | US | claimed |
| EP-1332150-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | Chattopadhyaya, Jyoti (SE) | 2003-08-06 | — | — | EP | claimed |
| WO-2003039523-A2 | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES | EXIQON A/S (DK) | 2003-05-15 | — | — | WO | claimed |
| WO-2002038578-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | CHATTOPADHYAYA JYOTI (SE) | 2002-05-16 | — | — | WO | claimed |
| EP-0739898-B1 | Phosphonomonoester nucleic acids, methods for their preparation and their use | AVENTIS PHARMA GMBH (DE) | 2001-09-26 | — | — | EP | claimed |
| US-5874553-A | ANTIBODIES; INHIBITOR OF GENE EXPRESSION | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-02-23 | — | — | US | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
| CN-109069572-A | Therapeutic compositions comprising peptides and uses thereof | 康德生物医疗技术公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-102690269-B | Trifluoro methyl substituted quinoline or quinoxaline compound and preparation method thereof, and pharmaceutical composition containing the compound and purpose thereof | SHANGHAI INST MATERIA MEDICA | 2015-01-07 | — | — | CN | disclosed |
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2338886-A2 | Naphthalene derivatives | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| WO-1986005519-A1 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD | SUMMERTON JAMES | 1986-09-25 | — | — | WO | disclosed |
| EP-0188400-A2 | Oligopeptides, intermediates and process for their preparation | CIBA-GEIGY AG (CH) | 1986-07-23 | — | — | EP | disclosed |
| EP-0168342-A1 | Process for the preparation of thrombin inhibitors | CIBA-GEIGY AG (CH) | 1986-01-15 | — | — | EP | disclosed |
| EP-0162208-A2 | Novel N-substituted 3,4-dihydropyrimidine derivatives, processes for preparing them and pharmaceutical compositions | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1985-11-27 | — | — | EP | disclosed |
| EP-0146785-A1 | Process for the preparation of protease inhibitors | CIBA-GEIGY AG (CH) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | RNASEH1, RNASEL, NSUN2 | TSHR 1258/4885LOXL2 1101/4885KCNJ1 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.